Correction: Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis

IF 13.4 1区医学 Q1 HEMATOLOGY Leukemia Pub Date : 2025-04-01 DOI:10.1038/s41375-025-02587-6

Daniele Capitanio, Francesca R. Calledda, Vittorio Abbonante, Daniele Cattaneo, Manuela Moriggi, Niccolò Bartalucci, Cristina Bucelli, Delfina Tosi, Umberto Gianelli, Alessandro Maria Vannucchi, Alessandra Iurlo, Cecilia Gelfi, Alessandra Balduini, Alessandro Malara

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

更正：蛋白质组学筛选确定PF4/Cxcl4是骨髓纤维化的关键驱动因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues

期刊最新文献

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study. Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat. CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.